Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Tuberculosis: New drug substance BTZ-043 is being tested on patients for the first time

11.12.2019

The Tropical Institute at the Hospital of the Ludwig-Maximilians-University (LMU) Munich is currently conducting a clinical study led by Professor Michael Hoelscher. Since mid-November, the first tuberculosis patients in Cape Town, South Africa, have been treated with the new drug substance BTZ-043 for the first time. The study is carried out within the PanACEA consortium in cooperation with the TASK Applied Science Clinical Research Centre, the University of Cape Town Lung Institute (UCTLI), and the Radboud University Medical Center.

BTZ-043 was discovered at the Leibniz Institute for Natural Product Research and Infection Biology - Hans Knöll Institute (Leibniz-HKI) in Jena. Since 2014, the new chemical entity has been developed in a consortium of scientists from the Leibniz-HKI and the Tropical Institute at the Hospital of the LMU Munich within the framework of the German Center for Infection Research (DZIF).


The study is funded by the German Federal Ministry of Education and Research (BMBF) and the European and Developing Countries Clinical Trials Partnership (EDCTP).

Tuberculosis is the most common cause of death worldwide caused by bacterial infections. According to the World Health Organization (WHO), approximately 1.5 million people die from tuberculosis every year, particularly in Southeast Asia, Africa and the Western Pacific region.

An enormous challenge in the treatment of tuberculosis is the increased incidence of resistant pathogens against which only a few antibiotics are still effective. The WHO is, therefore, placing great hopes in the development of drugs based on new chemical entities. BTZ-043, a benzothiazinone, is such a new drug candidate.

With the start of the study in Cape Town, the international research team has reached a decisive point: A Phase I study conducted in Germany showed good tolerability of BTZ-043. If BTZ-043 proves to be safe and effective in the current study (Phase II), this would be a major step in the development of a new drug. In the near future, this could replace one of the less effective drug compounds used in either standard or drug resistant therapy and contribute to a safer and/or shorter treatment of tuberculosis.

In the study, the BTZ-043 will be administered in two clinical centers in Cape Town to a total of 80 tuberculosis patients over a period of 14 days. The first step is to find an optimal dose for the drug candidate by achieving the best balance between efficacy and tolerability.

In the second step, these results will be confirmed in many more patients and both the efficacy and the tolerability will be compared with the current standard treatment for tuberculosis. All participating patients will be referred to a local health center 14 days after completion of their study. There, their treatment will be continued according to the national guidelines.

In mid-November 2019, the first patients for treatment with BTZ-043 were included in the study. First results on tolerability and efficacy are expected by the middle of next year.

After visiting the study site in Cape Town, Professor Michael Hoelscher from the Tropical Institute at the LMU Hospital expressed his optimism: "Following the promising results of the Phase I study in Germany, we see a great chance that the good tolerability of BTZ-043 will be confirmed in the treatment of tuberculosis patients. We are confident that we will also see good results in the first efficacy data."

Project Manager Dr. Julia Dreisbach from the Tropical Institute confirms: "In order to ensure patient safety, we are working together with our long-standing partners in South Africa and the most experienced study teams worldwide around Professors Andreas Diacon and Rodney Dawson.”

The development of new drugs, which are primarily intended for developing countries, is largely financed from public funds. Of note is that the first antibiotic developed in Germany in decades was achieved through cooperation between academic institutions. This is also a major achievement for the Federal Ministry of Education and Research, who in a strategic decision has decided to promote translational research in medicine through the establishment of the German Centres for Health Research.

The German Center for Infection Research (DZIF) with its Translational Project Management Office (TPMO) has scientifically accompanied and supported the preclinical and pharmaceutical development of BTZ-043. Further financing partners for the development of BTZ-043 are the consortium InfectControl 2020, which is funded by the BMBF, and the Free State of Thuringia.

As a sponsor, the LMU Hospital is responsible for the preclinical and clinical development as well as the quality and safety of the drug. The substance is manufactured by a medium-sized company, Hapila GmbH in Gera.

Wissenschaftliche Ansprechpartner:

Media contact:

Professor Michael Hoelscher
Department of Infectious Diseases and Tropical Medicine
Division of Infectious Diseases and Tropical Medicine
Hospital of the Ludwig-Maximilians-University (LMU) Munich
Leopoldstraße 5
80802 Munich, Germany
Phone: +49 (0) 89/4400 – 598-01
Email: hoelscher@lrz.uni-muenchen.de

Weitere Informationen:

http://www.klinikum.uni-muenchen.de
http://www.tropinst.med.uni-muenchen.de

Philipp Kressirer | idw - Informationsdienst Wissenschaft

Further reports about: BMBF Infectious Diseases LMU Tropical Medicine TuBerculosis

More articles from Health and Medicine:

nachricht Possible Alzheimer's breakthrough suggested
22.01.2020 | Case Western Reserve University

nachricht Body's natural signal carriers can help melanoma spread
21.01.2020 | University of Eastern Finland

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New roles found for Huntington's disease protein

Crucial role in synapse formation could be new avenue toward treatment

A Duke University research team has identified a new function of a gene called huntingtin, a mutation of which underlies the progressive neurodegenerative...

Im Focus: A new look at 'strange metals'

For years, a new synthesis method has been developed at TU Wien (Vienna) to unlock the secrets of "strange metals". Now a breakthrough has been achieved. The results have been published in "Science".

Superconductors allow electrical current to flow without any resistance - but only below a certain critical temperature. Many materials have to be cooled down...

Im Focus: Programmable nests for cells

KIT researchers develop novel composites of DNA, silica particles, and carbon nanotubes -- Properties can be tailored to various applications

Using DNA, smallest silica particles, and carbon nanotubes, researchers of Karlsruhe Institute of Technology (KIT) developed novel programmable materials....

Im Focus: Miniature double glazing: Material developed which is heat-insulating and heat-conducting at the same time

Styrofoam or copper - both materials have very different properties with regard to their ability to conduct heat. Scientists at the Max Planck Institute for Polymer Research (MPI-P) in Mainz and the University of Bayreuth have now jointly developed and characterized a novel, extremely thin and transparent material that has different thermal conduction properties depending on the direction. While it can conduct heat extremely well in one direction, it shows good thermal insulation in the other direction.

Thermal insulation and thermal conduction play a crucial role in our everyday lives - from computer processors, where it is important to dissipate heat as...

Im Focus: Fraunhofer IAF establishes an application laboratory for quantum sensors

In order to advance the transfer of research developments from the field of quantum sensor technology into industrial applications, an application laboratory is being established at Fraunhofer IAF. This will enable interested companies and especially regional SMEs and start-ups to evaluate the innovation potential of quantum sensors for their specific requirements. Both the state of Baden-Württemberg and the Fraunhofer-Gesellschaft are supporting the four-year project with one million euros each.

The application laboratory is being set up as part of the Fraunhofer lighthouse project »QMag«, short for quantum magnetometry. In this project, researchers...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

11th Advanced Battery Power Conference, March 24-25, 2020 in Münster/Germany

16.01.2020 | Event News

Laser Colloquium Hydrogen LKH2: fast and reliable fuel cell manufacturing

15.01.2020 | Event News

„Advanced Battery Power“- Conference, Contributions are welcome!

07.01.2020 | Event News

 
Latest News

New self-assembled monolayer is resistant to air

22.01.2020 | Life Sciences

Ultrafast camera takes 1 trillion frames per second of transparent objects and phenomena

22.01.2020 | Power and Electrical Engineering

Mosquitoes are drawn to flowers as much as people -- and now scientists know why

22.01.2020 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>